Search

Displaying results 1901 - 1910 of 10000 in total
  1. Drug

    Clostridium tetani

    go.drugbank.com/drugs/DB09876
    ApprovedInvestigational

    Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, Boostrix Polio - Injektionssuspension in einer Fertigspritze
  2. Drug

    Neomycin

    go.drugbank.com/drugs/DB00994
    ApprovedInvestigationalVet approved

    [A191529] Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. … [L10532] Neomycin is also used in combination with [polymyxin B] sulfates and [dexamethasone] in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye.

    Mixtures: LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO, LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIOProducts: N-bac cream, TP-NEOCIN 500 WSP NEOMYCIN SULPHATE 500MG/G POWDER
  3. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    safer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.

  4. Drug

    Estetrol

    go.drugbank.com/drugs/DB12235
    ApprovedInvestigational

    Estetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]

  5. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.

  6. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    it in collaboration with Eli Lilly and Company. … [L15316, L15321] Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk

  7. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen

    go.drugbank.com/drugs/DB10285
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

    Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
  8. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients with Alagille syndrome. It was granted FDA approval on 29 September 2021.

  9. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

  10. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]